Posted on

January 2024: Send-Out Test Delays Caused by Weather

Immediate Test Notification

January 2024: Send-Out Test Delays Caused by Weather

Due to the recent winter weather, there are ongoing delays in the shipment of specimens from Cleveland Clinic Laboratories to reference laboratories, including ARUP, Mayo, LabCorp, Quest, National Jewish, Eurofins Viracor, and others.

Transportation vendors are working through operational backlogs, and we are communicating with vendors to ensure sample stability and perform testing as quickly as possible.

Please get in touch with your CCL Sales Manager or Client Services with any questions.

Posted on

2024 Cleveland Clinic Laboratories Soft Tissue Pathology Course – Registration Now Open

Clinical Updates

Comprehensive & Immersive Soft Tissue Pathology Course

May 16-19, 2024

InterContinental Hotel at Cleveland Clinic Main Campus | Cleveland, OH

Join us for an Interactive, Immersive, and Comprehensive Soft Tissue Pathology Course

This four-day course is a one-of-a-kind experience set in the heart of one of the country’s busiest soft tissue pathology consultation practices.

Participants will have the opportunity to digitally preview a wide variety of soft tissue cases spanning from benign lesions and reactive mimics to high grade sarcomas, followed by interactive case-based discussions with world-renown faculty. Interspersed lectures focusing on a practical approach to common diagnostic scenarios will complement these case sessions.

During this course, pathologists will develop skills and tools to work-up and triage mesenchymal lesions encountered in every-day practice.

Symposium Director

Karen Fritchie, MD

Karen Fritchie, MD
Director, Soft Tissue Pathology

Course Objectives

  • Comprehend the utility of immunohistochemical, molecular techniques, and radiology studies in the work-up of soft tissue tumors
  • Develop a work-up strategy for the diagnosis of mesenchymal neoplasms
  • Identify common and uncommon soft tissue tumors
  • Recognize pitfalls commonly encountered in soft tissue pathology

Course Includes:

• Access to over 100 digital soft tissue cases
• Opportunity to tour our CCF pathology department
• Designated time for questions and discussion with faculty
• After-hours reception with participants and staff

Who Should Attend? 

Pathologists, Pathology Residents & Fellows

CME Credits

This live activity is approved for continuing medical education credits.  Read more.

Faculty Presenters

John Goldblum, MD

John Goldblum, MD
Chair, Department of Pathology

John Reith, MD
Staff Pathologist, Orthopaedic Pathology

Steven D. Billings, MD

Steven D. Billings, MD
Staff Pathologist, Dermatopathology & Soft Tissue Pathology

Scott Kilpatrick, MD

Scott Kilpatrick, MD
Director, Orthopaedic Pathology
Medical Director, Cleveland Clinic Laboratories

Brian Rubin, MD, PhD

Brian Rubin, MD, PhD
Chair, Pathology & Laboratory Medicine Institute

Josephine Dermawan, MD, PhD

Josephine Dermawan, MD, PhD
Director, AP Molecular Pathology
Staff Pathologist, Soft Tissue & Orthopaedic Pathology

Jesse McKenney, MD

Jesse McKenney, MD
Staff Pathologist, Genitourinary & Gynecologic Pathology

Registration

Visit clevelandclinicmeded.com/live/courses/comprehensivesofttissue/ for complete registration information.

In-person fee includes:
Continental breakfasts, refreshment breaks, Saturday reception (in-person only), and online access to faculty PowerPoint presentations in PDF format pre and post-course.

Virtual option fee includes:
Access to view lectures and online access to faculty PowerPoint presentations.

Early Bird
on or before April 1, 2024

After
April 1, 2024

Physician (MD, Scientist, PhD)

$699

$749

Resident* / Fellow*

$349

$399

Non-Physician

$349

$399

*A letter from the program director is required to receive the discounted fee. If the letter is not received two weeks prior to the activity, the full physician fee will be charged.

Group Discount Available
Groups of three or more from the same office/institution will receive a $100 discount on the full registration fee. Registrants must call 216.444.9990 to receive a promotional code for special pricing.

Registration and Cancellation
Preregistrations are accepted until 11:59 p.m. ET on Monday, May 13, 2024. Register onsite after this date. Contactless registration on your own device will be required.
In case of cancellation, an email notification is required to process your refund. A full refund will be issued if canceled by May 2, 2024. After May 2, 2024, a $125 cancellation fee will be deducted from your refund. No refunds will be issued after May 6, 2024.

For questions about registration or cancellation, email cmeregistration@ccf.org or call 216.448.8710.

Cleveland Clinic Center for Continuing Education reserves the right to cancel or postpone an activity at our sole discretion. In the unlikely event that this occurs, any registration fee(s) paid will be refunded. Be advised that Cleveland Clinic is not responsible for related costs including airline tickets, hotel costs, or any similar fee penalties incurred as a result of any meeting cancellations or changes.

General Information

Visit clevelandclinicmeded.com/live/courses/comprehensivesofttissue/ for complete registration information.

Location
InterContinental Cleveland
Cleveland Clinic Main Campus
9801 Carnegie Avenue
Cleveland, OH 44106
216.707.4100
iccleveland.com

Hotel Accommodations
A limited block of rooms has been reserved at the InterContinental Cleveland through April 16, 2024, at 5 p.m. EDT.

To make reservations, please call the Hotel Reservation Department at 855.765.8709 and reference the CCF Soft Tissue Pathology Program or reserve online at https://www.clevelandclinicmeded.com/live/courses/comprehensivesofttissue/ to receive the special rate of $209, plus tax.

Faculty Disclosure
The Cleveland Clinic Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Integrity and Independence requiring mitigation of all faculty conflicts of interest. Faculty declaring a relevant financial relationship will be identified in the activity syllabus.

For further information about this activity, contact Karen Fritchie, MD, at fritchk@ccf.org.

Americans with Disabilities Act
Cleveland Clinic Center for Continuing Education fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you need assistance, please notify us at least two weeks prior to the activity.

Accreditation
In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation
American Medical Association (AMA)
Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 28.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

American Board of Pathology MOC (ABPath)
Successful completion of this CME activity, which includes participation in the evaluation component, earns 28.75 credits toward the Lifelong Learning requirement for the American Board of Pathology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit. Credit will be reported within 30 days of claiming credit.

Certificate of Participation
A certificate of participation will be provided to other healthcare professionals for requesting credits in accordance with their professional boards and/or associations.

Study References
Faculty presentations will also be available online in PDF format pre and post-course. You will have access to download or print the slides.

Health and Safety
As participants are responsible for their own health choices, the use of masks by all participants at this event is optional. Additionally, attendees are not required to verify vaccination status nor to provide a negative COVID-19 test for entry. Please note this is subject to change based on the most recent status of CDC, local and/or state guidelines.

Agenda

Thursday, May 16, 2024

7:30 am          Continental Breakfast

8:00 am          Course Introduction and Welcoming Remarks – Karen Fritchie, MD

8:15 am          Slide Preview, Staff Q&A

 

11:00 am        LunchOn Your Own

 

12:00 pm        When (and when not) to do MDM2 fluorescence in situ hybridization  Karen Fritchie, MD

1:00 pm          Adipocytic tumors (slide review) – John Goldblum, MD

 

2:30 pm          Break

 

3:00 pm          Smooth muscle/pericytic tumors and their mimics (slide review) – John Goldblum, MD

4:00 pm          Soft tissue tumors with skeletal muscle differentiation (slide review) – Scott Kilpatrick, MD

5:00 pm          Matrix-forming mesenchymal neoplasms (slide review) – Karen Fritchie, MD

 

6:00 pm          Adjourn

Friday, May 17, 2024

7:30 am          Continental Breakfast

8:00 am          Slide Preview, Staff Q&A

 

10:15 am         Tour of Cleveland Clinic’s Department of Pathology Optional (non-CME)

 

11:00 am         Lunch On your own

 

12:00 pm        Common myofibroblastic lesions (slide review) – Karen Fritchie, MD

1:30 pm          Practical approach to uterine mesenchymal neoplasms Jesse McKenney, MD

2:30 pm          Fibrohistiocytic tumors Steven Billings, MD

 

3:00 pm          Break

 

3:30 pm          Practical approach to synovial biopsies – John Reith, MD

4:30 pm          Tumors of uncertain histiogenesisSteven Billings, MD

 

6:00 pm          Adjourn

Saturday, May 18, 2024

7:30 am          Continental Breakfast

8:00 am          Slide Preview, Staff Q&A

 

11:00 am         Lunch On your own

 

12:00 pm        Vascular tumors – Steven Billings, MD

1:30 pm          Diagnosing soft tissue tumors with “NextGen” immunohistochemistry Scott Kilpatrick, MD

 

3:00 pm          Break

 

3:30 pm          The importance of morphologic correlation with molecular resultsJosephine Dermawan, MD, PhD

 

6:00 pm          Reception with Attendees & Cleveland Clinic Staff

Sunday, May 19, 2024

7:30 am          Continental Breakfast

8:00 am          Slide Preview, Staff Q&A

10:00 am        Peripheral nerve sheath tumors Brian Rubin, MD, PhD

11:00 am        How to work up a pleomorphic sarcoma Karen Fritchie, MD

12:00 pm        Course Conclusion & Adjourn

Posted on

July 2023: Updates to Genital & Sexual Health Specimen Collection

Clinical Updates

Updates to Genital & Sexual Health Specimen Collection

Follow these guidelines for specimen submission in accordance with changes outlined in the May 2023 Technical Update.

Effective July 17, 2023, the laboratory will reject incorrectly submitted specimens.

Aptima® Multitest Swab Collection Kit

This kit is used for the following tests:

  • Gonorrhea & Chlamydia (GCCT)
  • Mycoplasma genitalium (MYGAMP)
  • Trichomonas vaginalis (TRVAMP)
  • Candida & Trichomonas (CVTV)
  • Bacterial Vaginosis (BVAMP)

Sample Type

Gonorrhea & Chlamydia (GCCT)

Mycoplasma genitalium (MYGAMP)

Trichomonas vaginalis (TRVAMP)

Candida & Trichomonas (CVTV)

Bacterial Vaginosis (BVAMP)

Clinician-Collected Vaginal Swab

Patient-Collected Vaginal Swab

Patient-Collected Penile Meatal Swab

✓ 

Clinician-Collected Throat Swab

Clinician-Collected Rectal Swab

FDA-approved and preferred

✓ 

FDA-approved and acceptable

FDA-approved but not recommended due to inferior
performance

*

Lab-Developed Test (not FDA-approved)

Aptima® Unisex Swab Collection Kit

This kit is used for the following tests:

  • Gonorrhea & Chlamydia (GCCT)
  • Mycoplasma genitalium (MYGAMP)
  • Trichomonas vaginalis (TRVAMP)

Sample Type

Gonorrhea & Chlamydia (GCCT)

Mycoplasma genitalium (MYGAMP)

Trichomonas vaginalis (TRVAMP)

Candida & Trichomonas (CVTV)

Bacterial Vaginosis (BVAMP)

Clinician-Collected Endocervical Swab

✓ 

✓ 

✓ 

Clinician-Collected Male Urethral Swab

✓ 

*

FDA-approved and preferred

✓ 

FDA-approved and acceptable

FDA-approved but not recommended due to inferior
performance

*

Lab-Developed Test (not FDA-approved)

Aptima® Urine Specimen Collection Kit

This kit is used for the following tests:

  • Gonorrhea & Chlamydia (GCCT)
  • Mycoplasma genitalium (MYGAMP)
  • Trichomonas vaginalis (TRVAMP)

Sample Type

Gonorrhea & Chlamydia (GCCT)

Mycoplasma genitalium (MYGAMP)

Trichomonas vaginalis (TRVAMP)

Candida & Trichomonas (CVTV)

Bacterial Vaginosis (BVAMP)

Female Urine

✓ 

*

Male Urine

✓ ✓

✓ ✓

*

FDA-approved and preferred

✓ 

FDA-approved and acceptable

FDA-approved but not recommended due to inferior
performance

*

Lab-Developed Test (not FDA-approved)

Aptima® Specimen Transfer Kit

Note: This can only be ordered as an add-on test by contacting Client Services.

This kit is used for the following tests:

  • Gonorrhea & Chlamydia (GCCT)
  • Trichomonas vaginalis (TRVAMP)

Sample Type

Gonorrhea & Chlamydia (GCCT)

Mycoplasma genitalium (MYGAMP)

Trichomonas vaginalis (TRVAMP)

Candida & Trichomonas (CVTV)

Bacterial Vaginosis (BVAMP)

ThinPrep® PreservCyt®

✓ 

FDA-approved and preferred

✓ 

FDA-approved and acceptable

FDA-approved but not recommended due to inferior
performance

*

Lab-Developed Test (not FDA-approved)

Posted on

July 2023: Updates to Recommended Myelodysplastic Syndrome Testing

Clinical Updates

Updates to Recommended Myelodysplastic Syndrome (MDS) Testing

Effective August 17, 2023.

Cleveland Clinic Laboratories’ Molecular Pathology & Cytogenomics section offers several testing options for individuals suspected to have Myelodysplastic Syndrome (MDS):

  • Chromosome Analysis Only  CHRBMH
  • Chromosome Analysis with reflex to FISH with MDS Panel* (if there are no chromosome results or the chromosome analysis was sub-optimalCHRMDS
  • Chromosome Analysis with reflex to Microarray (CMA)  BMCHF
  • FISH Only with MDS Panel*, blood  FSHMDS 
  • FISH Only with MDS Panel*, bone marrow  FSMDSM 

*MDS Panel contains FISH probes specific to chromosomes 5, 7, 8, and 20.

Testing Guidelines 

Per the National Comprehensive Cancer Network (NCCN) Myelodysplastic Syndromes Guidelines [version 1.2023 (09/12/22)] 

If standard cytogenetics (with ≥20 metaphases) cannot be obtained, a chromosome microarray [(CMA), also known as chromosome genomic array testing (CGAT)] or MDS-related fluorescence in situ hybridization (FISH) panel should be performed. If karyotype is normal, consider CMA. Note that CMA will detect not only somatic but constitutional (germline) changes. 

Recommended Testing

In keeping with the NCCN guidelines, Chromosome Analysis with Reflex to FISH (CHRMDS) is Cleveland Clinic Laboratories’ recommended test for individuals suspected to have MDS.

Discontinued Testing

Beginning August 17, 2023, the FISH Only with MDS Panel (FSHMDS & FSMDSM) for blood and bone marrow will be discontinued.
Note: Chromosome Analysis Only (CHRBMH) and Chromosome Analysis with reflex to Microarray (BMCHF) may still be ordered.

Questions?

Please contact your CCL Sales Manager or Client Services at 800.628.6816.

Posted on

Cleveland Clinic and LabConnect Announce Strategic Alliance

Clinical Update

Cleveland Clinic and LabConnect Announce Strategic Alliance

Collaboration on lab services will accelerate clinical trials to better impact patient care.

Cleveland Clinic Laboratories and LabConnect have announced a strategic alliance to accelerate clinical trials and connect patients to new medicines for improved patient care.

Through this alliance, LabConnect will utilize Cleveland Clinic Laboratories, the reference laboratory within Cleveland Clinic. LabConnect will leverage the health system’s extensive array of testing and assay validation services to support laboratory testing for an increasing number of clinical trials.

Posted on

CC-SIGN® Targeted Oncology Panel (TOP) by Next-Generation Sequencing

Clinical Updates

New Test: CC-SIGN® Targeted Oncology Panel (TOP) by Next-Generation Sequencing

Available to order starting on June 20, 2023.

A new, enhanced 59-gene hotspot Next-Generation Sequencing (NGS) panel is available for tumor DNA and RNA evaluation.

The Targeted Oncology Panel (TOP) is a custom 59-gene Next-Generation Sequencing (NGS) panel developed for the identification of single nucleotide variants (SNVs), small insertions and deletions (indels), and copy number gains (CNVs) from DNA specimens, and fusion transcripts and aberrant transcripts from RNA specimens.

The workflow allows for the concurrent testing of DNA and RNA to analyze over 1,000 biomarkers.

Targeted Oncology Panel by NGS

Order Codes
TOPTO (FFPE Tissue)
TOPCY (Cytology Alcohol or Formalin fixed cell block)
TOPBM (Bone Marrow Aspirate)
TOPPB (Peripheral Blood)

This test requires 5-10% tumor purity and does not evaluate circulating tumor DNA.

CPT Code
81445

Methodology
Next-Generation Sequencing

Specimen Type
FFPE Tissue
15 charged, unbaked, and unstained slides sectioned at 7 μm.
One pre and one post H&E slide with tumor area circled, and percent rumor indicated.

Cytology
15 charged, unbaked and unstained slides sectioned at 7 μm.
One H&E slide with tumor percent indicated.

Bone Marrow Aspirate
2 mL, Lavender K2EDTA Tube

Peripheral Blood
4 mL, Lavender K2EDTA Tube

Days Performed
2–3 times per week

Turnaround Time
8 days

Overview

Single nucleotide variants (SNVs), small insertions and deletions (indels), copy number gains, select fusions, and aberrant transcripts evaluated by this assay can aid in the diagnostic and therapeutic assessment of a variety of tumor types, including non-small cell lung cancer, melanoma, colorectal cancer, prostate cancer, breast cancer, glioblastoma, thyroid cancer, and others.

This panel can also provide focused tumor profiling for patients with locally advanced/metastatic disease, who are candidates for anti-cancer therapy, to identify uncommon but targetable alterations. In particular, this panel can be utilized for small biopsies and cytology specimens that may not be amenable to more comprehensive genomic sequencing.

Targeted Genes & RNA Fusions

For a full list of targeted genes & RNA fusions, please refer to the Targeted Oncology Panel by Next-Generation Sequencing Technical Brief.

How to Order

Place an order through an electronic interface or complete a Molecular Oncology & Associated Biomarkers Requisition and submit it with the specimen(s).

Hot Spot Panel Discontinuation

The TOP NGS panel will replace solid tumor hotspot mini-panels (Lung, Colorectal, Melanoma, GIST, etc.), as all previously detected biomarkers are included in the new testing.

In situations where the mini-panels were previously used as part of an upfront diagnostic workup, pathologist diagnostic and reflex ordering will utilize TOP testing.

Posted on

May 2023: New Test – Clozapine (CLOZA)

Clinical Updates

New Test: Clozapine (CLOZA)

Effective May 23, 2023.

Therapeutic drug monitoring for clozapine will be offered as an in-house test starting Tuesday, May 23, 2023.

The current send-out test, Clozapine and Metabolites, Serum or Plasma, Quantitative (CLOZSP), currently sent out to ARUP Laboratories, will be discontinued on June 20, 2023.

Clozapine (CLOZA)

New Test – CLOZA

Specimen Type
Red Serum Tube (No Additive)

Methodology
Turbidimetric immunoassay

Result Components
Clozapine

Days Performed
Monday – Saturday

Turnaround Time
1-4 days

Clozapine results greater than 1000 ng/mL have been designated as urgent.

Sendout Test – CLOZSP

Specimen Type
Red Serum Tube (No Additive) or Lavender K2EDTA Tube

Methodology
Liquid chromatography-tandem mass spectrometry

Result Components
Clozapine
Norclozapine
Clozapine-N-Oxide

Days Performed
Sunday – Saturday

Turnaround Time
2-4 days

Posted on

May 2023: Changes to Legionella Diagnostic Testing (LEGPCR)

Clinical Updates

Changes to Legionella Diagnostic Testing (LEGPCR)

Effective May 2, 2023.

Improvements to Cleveland Clinic Laboratories’ Legionella PCR assay will result in the discontinuation of most Legionella cultures.

Beginning May 2, 2023, Legionella pneumophila PCR (LEGPCR) will include additional DNA targets for Legionella, including species other than Legionella pneumophila, and a target specific for Legionella pneumophila serogroup 1.

This assay design is modeled after the U.S. Centers for Disease Control & Prevention’s assay.1

Legionella pneumophila PCR (LEGPCR)

Specimen Requirements
Lower respiratory samples, including bronchoalveolar lavage (BAL) and sputa, will continue to be the acceptable specimen types for PCR.

Results
Possible interpretations of test results include:

  • Legionella pneumophila Serogroup 1 Detected
  • Legionella pneumophila (not Serogroup 1) Detected
  • Legionella species (not pneumophila) Detected

Additional Updates
Beginning May 23, 2023, routine culture for Legionella spp. (LEGCUL) will be discontinued, but culture will reflexively be performed on any sample with detectable Legionella DNA by PCR.

Note: There is no change to Legionella urine antigen (LEGUAG) testing.

Reference

1 Benitez AJ, Winchell JM. Clinical application of a multiplex real-time PCR assay for simultaneous detection of Legionella species, Legionella pneumophila, and Legionella pneumophila serogroup 1. J Clin Microbiol. 2013 Jan;51(1):348-51. doi: 10.1128/JCM.02510-12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536254/pdf/zjm348.pdf

Posted on

2024 Cleveland Clinic Multispecialty Pathology Symposium – Register Now!

Clinical Updates

2024 Cleveland Clinic Multispecialty Pathology Symposium

January 26-28, 2024  |  Wynn Las Vegas

Overview

This pathology symposium will focus on practical discussions of commonly encountered problems in surgical pathology. The goal is to provide useful tips that the speakers utilize in their own practice at the microscope. We aim to address and discuss common problems and avoid an undue focus on esoterica.

In this course, renowned subspecialists who are highly sought-after for their teaching skills will cover a broad spectrum of cases, including genitourinary pathology, thoracic pathology, gastrointestinal and soft tissue pathology, gynecologic cancer, and breast pathology.

Practicing pathologists, fellows, and residents who attend will maintain, develop, and increase their knowledge, competence, and professional performance, with the intent to improve diagnosis and positively impact patient care.

Target Audience: Pathologists, Pathology Residents & Fellows

This activity has been approved for AMA PRA Category 1 credit™.

Symposium Co-Directors

Sanjay Mukhopadhyay, MD

Sean Williamson, MD

Sean Williamson, MD

Faculty Presenters

John Goldblum, MD

John Goldblum, MD

Amy Joehlin-Price, MD

Amy Joehlin-Price, MD

Andrew Sciallis, MD

Andrew Sciallis, MD

Agenda

Friday, January 26, 2024

7:00 am           Registration, Continental Breakfast, and Exhibits

8:00 am           Welcoming RemarksSean Williamson, MD, and Sanjay Mukhopadhyay, MD

 

Genitourinary Pathology

8:10 am           Pattern Based Approach to Renal Cell TumorsSean Williamson, MD

9:00 am           What’s New in Prostate Cancer Pathology?Sean Williamson, MD

9:45 am           Question & Answer Period

10:00 am         Refreshment Break and Exhibits

 

GI and Soft Tissue Pathology

10:30 am         Barrett’s Esophagus and BE-related Dysplasia: A Practical Approach to the Most Common Problems John Goldblum, MD

11:15 am         IBD and IBD-related Dysplasia with a Focus on Unusual Variants of Ulcerative ColitisJohn Goldblum, MD

12:00 pm         Question & Answer Period

 

12:15 pm         Lunch served at Wynn Las Vegas

 

Pulmonary Pathology

1:15 pm           The New, the Exciting, and the Annoying. Updates in Lung Cancer in 2023 Sanjay Mukhopadhyay, MD

2:00 pm           What I Learned from Mistakes in Thoracic PathologySanjay Mukhopadhyay, MD

2:45 pm           Questions & Answer Period

3:00 pm           Refreshment Break and Exhibits

 

Gynecologic Pathology

3:30 pm           Practical Staging in Endometrial Cancer: Important Details Made EasierAmy Joehlin-Price, MD

4:15 pm           Classifying High Grade Endometrial Cancer: When Histotype Matters and WhyAmy Joehlin-Price, MD

5:00 pm           Question & Answer Period

 

5:15 pm           Adjourn

Saturday, January 27, 2024

7:15 am           Continental Breakfast and Exhibits

 

Breast Pathology

8:00 am           Problematic Intraductal Breast Lesions – Andrew Sciallis, MD

8:45 am           Papillary Neoplasms of the Breast – Andrew Sciallis, MD

9:30 am           Question & Answer Period

 

9:45 am           Refreshment Break and Exhibits

 

Pulmonary Pathology

10:15 am         10 Lung Tumors You Must Have in Your Toolbox – Sanjay Mukhopadhyay, MD

11:00 am         Mesothelioma and Thymoma: Tips and Tricks to Simplify Your Life – Sanjay Mukhopadhyay, MD

11:45 am         Question & Answer Period

 

12:00 pm         Lunch – On Your Own

 

GI and Soft Tissue Pathology

1:30 pm           Common Problems in Diagnosis and Terminology in Colorectal Polyps – John Goldblum, MD

2:15 pm           The Trouble with Fat: How to Handle the Most Common Lipomatous Tumors – John Goldblum, MD

3:00 pm           Question & Answer Period

 

3:15 pm           Refreshment Break and Exhibits

 

Genitourinary Pathology

3:45 pm           What’s New in Bladder Cancer Pathology? Sean Williamson, MD

4:30 pm           Common Challenges in Testicular Tumors Sean Williamson, MD

5:15 pm           Question & Answer Period

 

5:30 pm           Adjourn

Sunday, January 28, 2024

7:15 am           Continental Breakfast and Exhibits

 

Gynecologic Pathology

8:00 am           Ovarian Frozen Section Pathology: How What You Say Affects What They Do Amy Joehlin-Price, MD

8:45 am           Vulvar Squamous Cell Carcinoma: Why We’re Making It More Complicated and How to Think about It Simply Amy Joehlin-Price, MD

9:30 am           Question & Answer Period

 

9:45 am           Refreshment Break and Exhibits

 

Breast Pathology

10:15 am         Challenging Spindle Cell Lesions of the Breast Andrew Sciallis, MD

11:00 am         Fibroepithelial Lesions of the Breast: An OverviewAndrew Sciallis, MD

11:45 am         Question & Answer Period

 

12:00 pm         Closing Remarks – Sean Williamson, MD, and Sanjay Mukhopadhyay, MD

 

12:15 pm         Adjourn

Posted on

Pathology Insights: Tumors of the Lung with Sanjay Mukhopadhyay, MD

Pathology Insights Video Series

Tumors of the Lung

Presented by Sanjay Mukhopadhyay, MD

In this video, an expert pulmonary pathologist and director of Cleveland Clinic’s Pulmonary Pathology service briefly covers all lung tumor types – including all the subtypes of lung cancer – listed in the new (2021) World Health Organization classification. Dr. Mukhopadhyay then describes the primary pathologic features of these tumors with high-quality pathology images provided in most cases.

This video should be helpful for patients, surgeons, pulmonologists, oncologists, pathologists, residents, and medical students.

As part of our educational mission for our clients and communities, Cleveland Clinic Laboratories presents the Pathology Insights video series.
These short videos break down information about interesting pathology cases to better inform doctors, laboratory staff, patients, or anyone interested in the field of pathology. Each episode features important cases, methods, and practices that are personally presented by our staff pathologists.